Looking Beyond Checkpoint Inhibitor Monotherapy: Uncovering New Frontiers for Pancreatic Cancer Immunotherapy

Overview

Journal Mol Cancer Ther

Date 2024 Sep 23

PMID 39311547

Authors

Eileena F Giurini

Oliver Ralph

Sam G Pappas

Kajal H Gupta

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) stands out as one of the most aggressive and challenging tumors, characterized by a bleak prognosis with a mere 11% survival rate over 5 years in the United States. Its formidable nature is primarily attributed to its highly aggressive behavior and poor response to existing therapies. PDAC, being notably resistant to immune interventions, presents a significant obstacle in treatment strategies. While immune checkpoint inhibitor therapies have revolutionized outcomes for various cancers, their efficacy in PDAC remains exceedingly low, benefiting less than 1% of patients. The consistent failure of these therapies in PDAC has prompted intensive investigation, particularly at the preclinical level, to unravel the intricate mechanisms of resistance inherent in this cancer type. This pursuit aims to pave the way for the development of novel immunotherapeutic strategies tailored to the distinct characteristics of PDAC. This review endeavors to provide a comprehensive exploration of these emerging immunotherapy approaches in PDAC, with a specific emphasis on elucidating their underlying immunological mechanisms. Additionally, it sheds light on the recently identified factors driving resistance to immunotherapy and evasion of the immune system in PDAC, offering insights beyond the conventional drivers that have been extensively studied.

References

Barilla R, Diskin B, Caso R, Lee K, Mohan N, Buttar C . Specialized dendritic cells induce tumor-promoting IL-10IL-17 FoxP3 regulatory CD4 T cells in pancreatic carcinoma. Nat Commun. 2019; 10(1):1424. PMC: 6441038. DOI: 10.1038/s41467-019-09416-2. View

Jin L, Tao H, Karachi A, Long Y, Hou A, Na M . CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019; 10(1):4016. PMC: 6728370. DOI: 10.1038/s41467-019-11869-4. View

Mirji G, Worth A, Bhat S, El Sayed M, Kannan T, Goldman A . The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Sci Immunol. 2022; 7(75):eabn0704. PMC: 9925043. DOI: 10.1126/sciimmunol.abn0704. View

Spranger S, Dai D, Horton B, Gajewski T . Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017; 31(5):711-723.e4. PMC: 5650691. DOI: 10.1016/j.ccell.2017.04.003. View

Frenel J, Le Tourneau C, ONeil B, Ott P, Piha-Paul S, Gomez-Roca C . Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017; 35(36):4035-4041. DOI: 10.1200/JCO.2017.74.5471. View

Qin H, Chen J, Bouchekioua-Bouzaghou K, Meng Y, Griera J, Jiang X . Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk. J Transl Med. 2023; 21(1):702. PMC: 10561406. DOI: 10.1186/s12967-023-04519-3. View

Merali N, Chouari T, Kayani K, Rayner C, Jimenez J, Krell J . A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2022; 14(4). PMC: 8870349. DOI: 10.3390/cancers14041020. View

Raj D, Nikolaidi M, Garces I, Lorizio D, Castro N, Caiafa S . CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2021; 27(5):1538-1552. DOI: 10.1158/1078-0432.CCR-19-2163. View

Pushalkar S, Hundeyin M, Daley D, Zambirinis C, Kurz E, Mishra A . The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018; 8(4):403-416. PMC: 6225783. DOI: 10.1158/2159-8290.CD-17-1134. View

10.

Le D, Lutz E, Uram J, Sugar E, Onners B, Solt S . Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013; 36(7):382-9. PMC: 3779664. DOI: 10.1097/CJI.0b013e31829fb7a2. View

11.

Derosa L, Routy B, Thomas A, Iebba V, Zalcman G, Friard S . Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022; 28(2):315-324. PMC: 9330544. DOI: 10.1038/s41591-021-01655-5. View

12.

Bockorny B, Grossman J, Hidalgo M . Facts and Hopes in Immunotherapy of Pancreatic Cancer. Clin Cancer Res. 2022; 28(21):4606-4617. DOI: 10.1158/1078-0432.CCR-21-3452. View

13.

Ochi A, Nguyen A, Bedrosian A, Mushlin H, Zarbakhsh S, Barilla R . MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med. 2012; 209(9):1671-87. PMC: 3428946. DOI: 10.1084/jem.20111706. View

14.

Raman V, Howell L, Bloom S, Hall C, Wetherby V, Minter L . Intracellular delivery of an exogenous immunization antigen refocuses CD8 T cells against cancer cells, eliminates pancreatic tumors and forms antitumor immunity. Front Immunol. 2023; 14:1228532. PMC: 10585021. DOI: 10.3389/fimmu.2023.1228532. View

15.

Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W . Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019; 178(4):795-806.e12. PMC: 7288240. DOI: 10.1016/j.cell.2019.07.008. View

16.

Laoui D, Keirsse J, Morias Y, Van Overmeire E, Geeraerts X, Elkrim Y . The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Commun. 2016; 7:13720. PMC: 5196231. DOI: 10.1038/ncomms13720. View

17.

Kamath S, Kalyan A, Kircher S, Nimeiri H, Fought A, Benson 3rd A . Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. Oncologist. 2019; 25(5):e808-e815. PMC: 7216436. DOI: 10.1634/theoncologist.2019-0473. View

18.

Henning J, Graffeo C, Rehman A, Fallon N, Zambirinis C, Ochi A . Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology. 2013; 58(2):589-602. PMC: 3638069. DOI: 10.1002/hep.26267. View

19.

Saka D, Gokalp M, Piyade B, Cevik N, Sever E, Unutmaz D . Mechanisms of T-Cell Exhaustion in Pancreatic Cancer. Cancers (Basel). 2020; 12(8). PMC: 7464444. DOI: 10.3390/cancers12082274. View

20.

Siolas D, Vucic E, Kurz E, Hajdu C, Bar-Sagi D . Gain-of-function p53 mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy. Cell Rep. 2021; 36(8):109578. PMC: 8687588. DOI: 10.1016/j.celrep.2021.109578. View